Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2024
Pharma News, 2024
Despite inquiry, FDA AdCom backs BMS Abecma approval
AdCom voted eight to three in favour of BMS and 2seventy bio’s CAR-T cell therapy, Abecma, in triple-class exposed multiple myeloma patients. Abecma is a B-cell maturation antigen (BCMA) dir...
Bristol Myers Squibb acquires Karuna Therapeutics for $14bn
BMS has acquired Karuna's lead asset, KarXT (xanomeline-trospium), along with its early-stage and pre-clinical pipeline.
Novartis begins expansion of Singapore biopharmaceutical plant
Novartis has broken ground on the expansion of its biopharmaceutical manufacturing facility in Singapore, which aims to meet the increasing demand in the Asian market.
Orchard follows buyout with FDA approval of rare disease gene therapy
The decision makes available in the U.S. a gene therapy GSK first began working on more than a decade ago.
AstraZeneca to acquire radioconjugate biotech Fusion in $2.4bn deal
As AstraZeneca looks to move past chemotherapy and radiotherapy, it will enter a market firmly controlled by Novartis.
FDA approves BeiGene’s TEVIMBRA for oesophageal cancer
The US Food and Drug Administration (FDA) has approved BeiGene’s TEVIMBRA (tislelizumab-jsgr) for the treatment of adults with unresectable or metastatic oesophageal squamous cell ca...
Advances in multiple myeloma treatment
March is Myeloma Awareness Month. Multiple myeloma is a blood cancer that most often occurs in people over age 45. It's the second-most common blood cancer and the most common blood cancer in Blac...
AstraZeneca snaps up Amolyt for $1.05bn to boost rare disease pipeline
AstraZeneca has signed a definitive agreement to acquire Amolyt Pharma, which specialises in therapies for rare endocrine diseases, in a deal worth $1.05bn.
Researchers identify mutation that alters Alzheimer's disease progression
The scientist of the Faculty of Medicine of the University of Malaga José Luis Royo has coordinated a study that summarizes eight years of research and brings together 100 multidisciplinary speci...
mmVira's oncolytic product MVR-T3011 IT Intratumoral Injection Receives FDA Fast Track Designation for HNSCC Treatment
SHENZHEN, China -- ImmVira has recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for oncolytic virus product MVR-T3011 IT (intratumoral...
Protein discovery sparks treatment hope for aggressive cancer
Treating acute lymphoblastic leukaemia cells with the drug CX-5461 disrupts the nucleolar ribosome machinery shown by the fibrillarin protein (green) in the nucleus (blue) that stimu...
Regeneron’s Praluent receives FDA approval for paediatric patients with genetic high cholesterol
Regeneron Pharmaceuticals has announced that its Praluent (alirocumab) injection has received extended approval from the US Food and Drug Administration (FDA) to include paediatric pat...
38
39
40
41
42
43
44
45
46
